Radiotherapy on-chip: microfluidics for translational radiation oncology.


Journal

Lab on a chip
ISSN: 1473-0189
Titre abrégé: Lab Chip
Pays: England
ID NLM: 101128948

Informations de publication

Date de publication:
31 05 2022
Historique:
pubmed: 29 4 2022
medline: 3 6 2022
entrez: 28 4 2022
Statut: epublish

Résumé

The clinical importance of radiotherapy in the treatment of cancer patients justifies the development and use of research tools at the fundamental, pre-clinical, and ultimately clinical levels, to investigate their toxicities and synergies with systemic agents on relevant biological samples. Although microfluidics has prompted a paradigm shift in drug discovery in the past two decades, it appears to have yet to translate to radiotherapy research. However, the materials, dimensions, design versatility and multiplexing capabilities of microfluidic devices make them well-suited to a variety of studies involving radiation physics, radiobiology and radiotherapy. This review will present the state-of-the-art applications of microfluidics in these fields and specifically highlight the perspectives offered by radiotherapy on-a-chip in the field of translational radiobiology and precision medicine. This body of knowledge can serve both the microfluidics and radiotherapy communities by identifying potential collaboration avenues to improve patient care.

Identifiants

pubmed: 35477748
doi: 10.1039/d2lc00177b
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2065-2079

Auteurs

Rodin Chermat (R)

μFO Lab, Polytechnique Montréal, Montréal, QC, Canada. rodin.chermat@polymtl.ca.
Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Maryam Ziaee (M)

μFO Lab, Polytechnique Montréal, Montréal, QC, Canada. rodin.chermat@polymtl.ca.
Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

David Y Mak (DY)

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.

Elena Refet-Mollof (E)

μFO Lab, Polytechnique Montréal, Montréal, QC, Canada. rodin.chermat@polymtl.ca.
Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Francis Rodier (F)

Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Département de radiologie, radio-oncologie et médecine nucléaire, Université de Montréal, Montreal, QC, Canada.

Philip Wong (P)

Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.

Jean-François Carrier (JF)

Département de radiologie, radio-oncologie et médecine nucléaire, Université de Montréal, Montreal, QC, Canada.
Département de Physique, Université de Montréal, Montréal, QC, Canada.
Département de Radio-oncologie, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.

Yuji Kamio (Y)

Département de Radio-oncologie, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada.
Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, Canada.

Thomas Gervais (T)

μFO Lab, Polytechnique Montréal, Montréal, QC, Canada. rodin.chermat@polymtl.ca.
Institut du Cancer de Montréal, (ICM), Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH